Related Experiment Videos
Detection of sequence-specific antitumor alkylating agent DNA damage from cells treated in culture and from a patient
G J Bubley1, G K Ogata, N P Dupuis
1Division of Hematology/Oncology, Beth Israel Hospital, Harvard Medical School, Boston, MA 02215.
Abstract:
Detection of sequence-specific DNA damage induced by antitumor alkylating agents might provide a mechanism for detecting and discriminating damage specific to one or more of these drugs. Using repetitive primer-extension and human alphoid DNA as a substrate, lesions specific for an activated form of cyclophosphamide, 4-hydroperoxycyclophosphamide, were detected at 32 of 33 guanines within a 200-base pair region in DNA from cells treated in culture. There was a marked variation in lesion site intensity among affected guanines. For instance, guanines flanked by cytosine were weak sites of 4-hydroperoxycyclophosphamide-induced damage. Damage at bases other than guanine induced by cisplatin, UV irradiation, and adozelesin were compared to drug-DNA lesions induced by 4-hydroperoxycyclophosphamide. Using this method it was possible to detect, and at some sites distinguish, between cyclophosphamide- and cisplatin-induced DNA damage within WBC DNA from a patient treated with both agents. There was a different damage pattern for DNA derived from cells treated in culture compared to DNA derived from the patient sample.
Insights
This study developed a method to detect specific DNA damage from antitumor drugs like cyclophosphamide. The technique successfully identified and differentiated drug-induced DNA lesions in patient samples.
Area of Science:
- Molecular Biology
- Toxicology
- Cancer Research
Background:
- Antitumor alkylating agents can cause sequence-specific DNA damage.
- Detecting and discriminating drug-induced DNA lesions is crucial for understanding drug mechanisms and patient responses.
Purpose of the Study:
- To develop a method for detecting and discriminating sequence-specific DNA damage induced by antitumor alkylating agents.
- To investigate the DNA damage patterns of 4-hydroperoxycyclophosphamide and compare them with other DNA-damaging agents.
Main Methods:
- Utilized repetitive primer-extension assays with human alphoid DNA as a substrate.
- Analyzed DNA from cultured cells and a patient treated with cyclophosphamide and cisplatin.
- Compared DNA damage patterns induced by 4-hydroperoxycyclophosphamide, cisplatin, UV irradiation, and adozelesin.
Main Results:
- Successfully detected 4-hydroperoxycyclophosphamide-specific lesions at 32 of 33 guanines within a 200-bp region.
- Observed variations in lesion intensity, with guanines flanked by cytosine showing weaker damage.
- Differentiated between cyclophosphamide- and cisplatin-induced DNA damage in a patient's white blood cell DNA.
- Noted distinct damage patterns between DNA from cultured cells and patient samples.
Conclusions:
- The developed method allows for the detection and discrimination of sequence-specific DNA damage induced by antitumor drugs.
- The findings highlight differential DNA damage patterns based on the agent, sequence context, and sample type (in vitro vs. in vivo).
- This approach holds potential for monitoring drug efficacy and toxicity in cancer patients.